LARS1

Leucine--tRNA ligase, cytoplasmic · Q9P2J5 · LARS1 on Sugi Atlas →

4,641 patent compounds predicted against LARS1, 2,267 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3049869	0.69	7/20
Trifluoroacetic Acid (SCHEMBL3007062)	0.38	7/20
Trifluoroacetic Acid (SCHEMBL3007067)	0.38	7/20
Hydrochloric Acid (SCHEMBL2679368)	0.97	5/20
Hydrochloric Acid (SCHEMBL2679371)	0.97	5/20
Hydrochloric Acid (SCHEMBL3446383)	0.61	5/20
SCHEMBL2679968	0.55	5/20
SCHEMBL3101143	0.53	5/20
SCHEMBL5891728	0.42	5/20
Trifluoroacetic Acid (SCHEMBL3652089)	0.36	5/20
SCHEMBL453500	1.00	4/20
SCHEMBL469460	1.00	4/20
Hydrochloric Acid (SCHEMBL462459)	0.75	4/20
SCHEMBL5019539	0.74	4/20
Hydrochloric Acid (SCHEMBL2678804)	0.73	4/20
Hydrochloric Acid (SCHEMBL2678806)	0.73	4/20
Hydrochloric Acid (SCHEMBL2679647)	0.73	4/20
SCHEMBL453354	0.73	4/20
SCHEMBL453410	0.73	4/20
SCHEMBL469428	0.73	4/20

Clinical trials — most relevant to LARS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.	PHASE1/PHASE2	COMPLETED
The KHENEREXT Study	PHASE2	COMPLETED
Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis	PHASE1	COMPLETED
Quantifying Disease Progression in LBSL	nan	UNKNOWN
Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)	nan	RECRUITING
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC	nan	UNKNOWN
Natural History of the Leukodystrophies	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Genomic of CONgenital Sideroblastic Anemias	nan	RECRUITING
Identification of New FTLD Genes	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Imaging Genetics of Laryngeal Dystonia	nan	RECRUITING
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Genetics of Familial and Sporadic ALS	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a LARS1 binder may also engage these)

Protein	Name	Similarity
Q5R614	—	1.000	Q5R614 →
Q8BMJ2	—	0.994	Q8BMJ2 →
F4I116	—	0.978	F4I116 →
Q8S9J2	—	0.963	Q8S9J2 →
Q6DIJ1	—	0.958	Q6DIJ1 →
Q5R8T5	—	0.956	Q5R8T5 →
YARS1	Tyrosine--tRNA ligase, cytoplasmic	0.956	landscape →
Q5ZJ08	—	0.955	Q5ZJ08 →
Q91WQ3	—	0.954	Q91WQ3 →
Q6TGS6	—	0.953	Q6TGS6 →
Q4KM49	—	0.952	Q4KM49 →
Q29465	—	0.951	Q29465 →
Q7ZX51	—	0.950	Q7ZX51 →
Q64514	—	0.948	Q64514 →
B4G0F3	—	0.948	B4G0F3 →
TPP2	Tripeptidyl-peptidase 2	0.947	landscape →
QARS1	Glutamine--tRNA ligase	0.947	landscape →
B9N1F9	—	0.946	B9N1F9 →
Q5R4R2	—	0.946	Q5R4R2 →
Q8BML9	—	0.945	Q8BML9 →
P97789	—	0.945	P97789 →
A0A0K9RL25	—	0.945	A0A0K9RL25 →
Q8IZH2	—	0.944	Q8IZH2 →
Q66H61	—	0.944	Q66H61 →
RNGTT	mRNA-capping enzyme	0.944	landscape →
Q5ZMA6	—	0.944	Q5ZMA6 →
Q5RFI8	—	0.943	Q5RFI8 →
P36871	—	0.943	P36871 →
HARS1	Histidine--tRNA ligase, cytoplasmic	0.943	landscape →
Q64560	—	0.943	Q64560 →